Little-known health care hedge fund firm RA Capital Management raised its profile Monday when it shelled out $200 million to invest in Novavax, a late-stage biotechnology company developing a vaccine for Covid-19.
RA Capital bought Series A convertible preferred stock, convertible into nearly 4.4
